Coreline Soft Co., Ltd. to Showcase Multi-Disease Analysis Technology for Chest CT at RSNA in the U.S.
Comprehensive Analysis of Pulmonary Nodules, Emphysema, and Coronary Artery Calcification… Secured 13 FDA Approvals
Supplied to Over 500 Medical Institutions in 19 Countries… Cumulative Image Analysis Exceeds 3.5 Million Cases
[Edaily Reporter NA EUN-KYUNG ] Coreline Soft Co., Ltd.(384470)is set to showcase medical artificial intelligence (AI) technology in the U.S. that analyzes information related to lung and cardiovascular diseases from a single chest computed tomography (CT) scan.
Coreline Soft Co., Ltd. announced on the 19th that it will participate in the Radiological Society of North America (RSNA 2026) conference, taking place in Chicago from the 29th through December 3. At the event, the company will introduce its “One CT, Multi-Disease” strategy, centered on its medical image analysis platform, “AVIEW.”
While chest CT scans are typically performed for lung cancer screening or the diagnosis of lung diseases, the images contain information related to various conditions—such as pulmonary emphysema and coronary artery calcification—in addition to pulmonary nodules. This is why “opportunistic screening”—the process of identifying additional disease risk information in previously acquired images—is gaining attention.
Coreline Soft Co., Ltd. uses AI to quantitatively analyze this information, supporting medical professionals in image interpretation and patient follow-up. At this exhibition, the company will showcase its lung nodule detection and follow-up solution “AVIEW LCS,” its chronic obstructive pulmonary disease (COPD) analysis solution “AVIEW COPD,” and its coronary artery calcification analysis solution “AVIEW CAC.”
Recently, “AVIEW Aorta Metrics,” which automatically measures aortic diameter, received 510(k) clearance from the U.S. Food and Drug Administration (FDA), bringing the company’s cumulative total of FDA clearances to 13.
At the academic conference, international researchers will also present the results of studies utilizing AVIEW. These include research comparing estimated lung function derived from chest CT images with actual pulmonary function test results, as well as studies quantitatively evaluating changes in the early stages of COPD and interstitial lung disease before and after treatment.
The company is also expanding its partnerships with overseas medical institutions. In the U.S., it is working with Infinite’s North American subsidiary to automatically integrate AI analysis capabilities into Picture Archiving and Communication Systems (PACS). In Germany, it is supporting multiple medical institutions in sharing diagnostic images and interpretation tasks.
According to the company, AView is currently used in more than 500 medical institutions across 19 countries, and the cumulative number of image analyses has exceeded 3.5 million.
A representative of Coreline Soft Co., Ltd. stated, “At this conference, we plan to present case studies that go beyond the detection of individual lesions to demonstrate how quantitative analysis results for various diseases have been applied to the actual clinical and screening systems of medical institutions.” Coreline Soft Co., Ltd. CI (Photo: Coreline Soft Co., Ltd.)
Korea Digital Exchange, which operates the digital asset (virtual asset) exchange Flybit, has taken steps to strengthen anti-money laundering measures and user protection. Korea Digital Asset Exchange…
NamyangDairyProducts(003920)’s protein brand “TakeFit” saw its cumulative sales for the third quarter of this year increase by 48.3% compared to the same period last year. Analysts attribute this grow…
Coreline Soft Co., Ltd.(384470)is set to showcase medical artificial intelligence (AI) technology in the U.S. that analyzes information related to lung and cardiovascular diseases from a single chest …